Browsing Tag

AFM24

Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of…

Eli Pacheco May 26, 2023 0

AFM24-101 phase 1/2 results in 10 patients from the non-small cell lung cancer (NSCLC) cohort demonstrated clinical activity and a well-managed safety profile in heavily pretreated patients…

Health

Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the…

Eli Pacheco May 27, 2022 0

Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy in patients with advanced EGFR-expressing solid tumorsDesign and rationale of the phase 1/2a…

Health

Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study…

Eli Pacheco Apr 9, 2022 0

The recommended phase 2 dose was determined at 480 mgAFM24 has demonstrated a well-managed safety profilePharmacodynamic activity was observed at doses of 160 mg and higherThe maximum…

Health

Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a…

Eli Pacheco Nov 8, 2021 0

Patient recruitment is open for the first-in-human proof of concept trial of the combination of AFM24 and SNK01 NK cells in three advanced or metastatic EGFR-expressing cancers, namely…